Ifosfamide, Carboplatin, and Etoposide: A Highly Effective Cytoreduction and Peripheral-Blood Progenitor-Cell Mobilization Regimen for Transplant-Eligible Patients With Non-Hodgkin's Lymphoma
Craig H. Moskowitz(Memorial Sloan Kettering Cancer Center), Andrew D. Zelenetz(Memorial Sloan Kettering Cancer Center), David B. Agus(Cedars-Sinai Medical Center), Ariela Noy, Barrett H. Childs(Florida Hospital Cancer Institute), Richard C. Frank(Memorial Sloan Kettering Cancer Center), Stephen D. Nimer(University of Miami), Eric Hedrick(Biogen (United States)), Nancy Coady-Lyons(Memorial Sloan Kettering Cancer Center), Joseph G. Jurcic(Memorial Sloan Kettering Cancer Center), Sonia Hunte(Memorial Sloan Kettering Cancer Center), André Goy(Rutgers, The State University of New Jersey), Jill R. Glassman, Joseph R. Bertino(Rutgers, The State University of New Jersey), James P. O’Brien(Memorial Sloan Kettering Cancer Center), Diane C. Louie(Memorial Sloan Kettering Cancer Center), David Straus(Memorial Sloan Kettering Cancer Center), Daniel A. Filippa(Memorial Sloan Kettering Cancer Center), Carol S. Portlock(Memorial Sloan Kettering Cancer Center), Joachim Yahalom
Cited by 303
Related Papers
Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma
|New England Journal of Medicine|2018|2.3k
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2013|2.2k
Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2014|1.7k
The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee
|Blood|2022|1.5k
Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies
|Journal of Clinical Oncology|2012|1.1k